2020 Start of COVID studies

With the advent of the COVID-19 pandemic, the Norton lab joined forces with other Tulane Investigators including Dr. James Robinson, Dr. John Schieffelin, Dr. Kevin Zwezdaryk, Dr. Stacy Dr. Jay Kolls, Dr. Sam Landry to investigate factors driving immunologic responses. With a NIH/NCI funded Seronet Center program grant we created the Tulane University COVID Antibody and Immunity Network (TUCAIN). Our lab will head up Project 2 investigating cellular immunity to infection. The grant began in October 2020, and as with COVID is continually evolving. Recent studies supported by this work include the following with many more in the works!

  1. Dietrich M.L.,Norton E.B., Elliott D., Smira A.R., Rouelle J.A., Bond N.G., Aime-Marcelin K., Prystowsky A., Kemnitz R., Sarma A., Himmelfarb S.T., Sharma N., Stone A.E., Craver R., Lindrose A.R., Smitley L.A., Uddo R.B., Myers L., Drury S.S., Schieffelin J.S., Robinson J.E., Zwezdaryk K.J.
    SARS-CoV-2 Seroprevalence Rates of Children in Louisiana During the State Stay at Home Order.

    medRXiv 2020.07.07.20147884 [Preprint] July 08, 2020. Available from:


  2. Huang Z, Ning B, Yang HS, Youngquist BM, Niu A, Lyon CJ, Beddingfield BJ, Fears AC, Monk CH, Murrell AE, Bilton SJ, Linhuber JP, Norton EB, Dietrich ML, Yee JK, Lai W, Scott JW, Yin XM, Rappaport J, Robinson JE, Saba NS, Roy CJ, Zwezdaryk KJ, Zhao Z, Hu TY. Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection. J Clin Invest. 2021 Feb 9;. doi: 10.1172/JCI146031. [Epub ahead of print] PubMed PMID: 33561010.
  3. Schieffelin JS, Norton EB, Kolls JK. What should define a SARS-CoV-2 “breakthrough” infection?. J Clin Invest. 2021 Jun 15;131(12). doi: 10.1172/JCI151186. PubMed PMID: 33974565; PubMed Central PMCID: PMC8203469.

Leave a Reply

Your email address will not be published.